JOSÉ
HERNÁNDEZ QUERO
Investigador desde 2023
Hospital Universitario Reina Sofia
Córdoba, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Reina Sofia (27)
2022
-
Epidemiological trends of HIV/HCV coinfection in Spain, 2015–2019
HIV Medicine, Vol. 23, Núm. 7, pp. 705-716
-
High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use
Journal of Infection, Vol. 85, Núm. 3, pp. 322-326
-
Predictors of low-level HIV viraemia and virological failure in the era of integrase inhibitors: A Spanish nationwide cohort
HIV Medicine, Vol. 23, Núm. 8, pp. 825-836
2021
-
Progression to hepatitis C virus micro-elimination in people living with HIV in Spain
Clinical Microbiology and Infection
2019
-
Brief Report: Response to Hepatitis A Virus Vaccine in HIV-Infected Patients Within a Retrospective, Multicentric Cohort: Facing Hepatitis A Outbreaks in the Clinical Practice
Journal of Acquired Immune Deficiency Syndromes, Vol. 81, Núm. 1, pp. E1-E5
-
Prevalence of resistance associated substitutions and efficacy of baseline resistance-guided chronic hepatitis C treatment in Spain from the GEHEP-004 cohort
PLoS ONE, Vol. 14, Núm. 8
2018
-
Human immunodeficiency virus/hepatits C virus coinfection in Spain: Elimination is feasible, but the burden of residual cirrhosis will be significant
Open Forum Infectious Diseases, Vol. 5, Núm. 1
-
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: Results of the neurocognitive substudy of the SALT randomized clinical trial
Journal of Antimicrobial Chemotherapy, Vol. 73, Núm. 9, pp. 2444-2451
2017
-
Genotypic tropism testing of proviral DNA to guide maraviroc initiation in aviraemic subjects: 48-week analysis of results from the PROTEST study
HIV Medicine, Vol. 18, Núm. 7, pp. 482-489
-
Impact of universal access to hepatitis C therapy on HIV-infected patients: implementation of the Spanish national hepatitis C strategy
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 36, Núm. 3, pp. 487-494
-
Quorum sensing network in clinical strains of A. baumannii: AidA is a new quorum quenching enzyme
PLoS ONE, Vol. 12, Núm. 3
-
Response to bile salts in clinical strains of Acinetobacter baumannii lacking the adeABC efflux pump: Virulence associated with quorum sensing
Frontiers in Cellular and Infection Microbiology, Vol. 7, Núm. MAY
-
Simplification to dual therapy (atazanavir/ritonavir1lamivudine) versus standard triple therapy [atazanavir/ritonavir1two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
Journal of Antimicrobial Chemotherapy, Vol. 72, Núm. 1, pp. 246-253
2016
-
Hepatic safety of rilpivirine/emtricitabine/tenofovir disoproxil fumarate fixed-dose single-tablet regimen in HIV-infected patients with active hepatitis C virus infection: The hepatic study
PLoS ONE, Vol. 11, Núm. 5
-
Human immunodeficiency virus/hepatitis C virus coinfection in Spain: Prevalence and patient characteristics
Open Forum Infectious Diseases, Vol. 3, Núm. 2
2015
-
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 775-784
2014
2012
-
Safety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy
European Journal of Clinical Microbiology and Infectious Diseases, Vol. 31, Núm. 8, pp. 1771-1774
2011
-
Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients
AIDS, Vol. 25, Núm. 6, pp. 761-766
-
Eficacia y seguridad de daptomicina en dosis elevadas (≥ 8 mg/kg/día)
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 29, Núm. 6, pp. 425-427